Immunotherapy, particularly checkpoint inhibitors, such as pembrolizumab or nivolumab, should be considered for patients with high PD-L1 expression, microsatellite instability (MSI-high), or high tumor mutational burden (TMB). This evidence concerns the gene CD274 and neoplasm.